Effectiveness of psychological interventions in preventing recurrence of depressive disorder: Meta-analysis and meta-regression

Biesheuvel-Leliefeld, Karolien E M; Kok, Gemma; Bockting, Claudi; Cuijpers, Pim; Hollon, Steven D.; Marwijk, Harm van; Smit, Filip

doi:10.1016/j.jad.2014.12.016

Cited by 143 publications

(141 citation statements)

References 59 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…Protein levels of sEH in the parietal cortex from depression, bipolar disorder, and schizophrenia were significantly higher than those on controls. One-way ANOVA showed the results [F (3,56) = 4.364, P = 0.008]. Data are shown as mean ± SEM (n = 15).…”

Section: Discussionmentioning

confidence: 89%

“…(D) Western blot analysis of sEH in the cerebellum from control (n = 15), depression (n = 15), bipolar disorder (n = 15), and schizophrenia (n = 15). Protein levels of sEH in the cerebellum from depression, bipolar disorder, and schizophrenia were not different among the four groups [F (3,56) =1.389, P = 0.256]. Data are shown as mean ± SEM (n = 15).…”

Section: Discussionmentioning

confidence: 99%

“…However, approximately two-thirds of depressed patients fail to respond fully to pharmacotherapy. Furthermore, there is a high rate of relapse, and depressed patients have a high risk of committing suicide (2)(3)(4).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Ren

Ishima

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

127

150

View full text Add to dashboard Cite

Depression is a severe and chronic psychiatric disease, affecting 350 million subjects worldwide. Although multiple antidepressants have been used in the treatment of depressive symptoms, their beneficial effects are limited. The soluble epoxide hydrolase (sEH) plays a key role in the inflammation that is involved in depression. Thus, we examined here the role of sEH in depression. In both inflammation and social defeat stress models of depression, a potent sEH inhibitor, TPPU, displayed rapid antidepressant effects. Expression of sEH protein in the brain from chronically stressed (susceptible) mice was higher than of control mice. Furthermore, expression of sEH protein in postmortem brain samples of patients with psychiatric diseases, including depression, bipolar disorder, and schizophrenia, was higher than controls. This finding suggests that increased sEH levels might be involved in the pathogenesis of certain psychiatric diseases. In support of this hypothesis, pretreatment with TPPU prevented the onset of depression-like behaviors after inflammation or repeated social defeat stress. Moreover, sEH KO mice did not show depressionlike behavior after repeated social defeat stress, suggesting stress resilience. The sEH KO mice showed increased brain-derived neurotrophic factor (BDNF) and phosphorylation of its receptor TrkB in the prefrontal cortex, hippocampus, but not nucleus accumbens, suggesting that increased BDNF-TrkB signaling in the prefrontal cortex and hippocampus confer stress resilience. All of these findings suggest that sEH plays a key role in the pathophysiology of depression, and that epoxy fatty acids, their mimics, as well as sEH inhibitors could be potential therapeutic or prophylactic drugs for depression.brain-derived neurotrophic factor | depression | epoxyeicosatrienoic acid | soluble epoxide hydrolase | resilience

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Ren

Ishima

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

127

150

View full text Add to dashboard Cite

show abstract

“…L'efficacité des psychothérapies a été largement démontrée sur la rémission des symptômes et sur la persistance des effets et la préven-tion des rechutes (Roth et Fonagy, 2005 ;INSERM, 2004 ;Lambert, 2013 ;Wampold, 2013 ;Biesheuvel-Leliefeld, Kok, Bockting, et al, 2015) et de nombreuses études médico-économiques ont démontré un impact positif du recours aux psychothérapies sur les consultations médicales, les hospitalisations, la consommation de médicaments, en réduisant la consommation de ces services et leurs coûts directs associés, ainsi que sur les coûts indirects, en particulier sur les arrêts de travail (deMaat, Philipszoon, Schoevers et al, 2007 ;Abass, Kisely, Rasic et al, 2015). Les études ont aussi montré que les psychothérapies contribuent à améliorer la qualité de vie des patients et de leur entourage (Hertenstein, Thiel, Herbst et al, 2013).…”

Section: Contexte De L'étudeunclassified

Coûts et bénéfices d’un programme de financement des psychothérapies auprès des Français souffrant de troubles dépressifs ou anxieux

Dezetter

Briffault

2016

smq

View full text Add to dashboard Cite

Les psychothérapies structurées sont des traitements des troubles dépressifs ou anxieux recommandés par les guides de bonne pratique internationaux, dont l’efficacité et l’impact positif sur la santé et les coûts, ont été largement démontrés. Toutefois en France, malgré le lourd fardeau économique que ces troubles représentent, les psychothérapies effectuées avec un psychothérapeute non-médecin ne sont pas remboursées.L’étude vise à évaluer les coûts et bénéfices qu’un programme de prise en charge partiel des psychothérapies permettrait pour les Français souffrant de troubles dépressifs ou anxieux.Les données sont issues d’une enquête transversale portant sur 20 777 adultes en population générale. L’évaluation économique s’est inspirée de la méthodologie du programme anglais Improving Access for Psychological Therapies adaptée à la France. Le coût de la séance a été estimé à 41 EUR, le taux de remboursement à 60 % ; les coûts annuels induits par les troubles dépressifs à 4 702 EUR, par les troubles anxieux à 1 500 EUR ; et le taux de rémission attribuable aux psychothérapies à 30 % +/-10 %.Résultats Pour le suivi moyen de 12,1 séances, le coût du suivi psychothérapeutique annuel s’élèverait à 308 millions EUR pour le régime obligatoire, pour traiter 2,3 % de la population. Le ratio coût-bénéfice de la psychothérapie s’élèverait, pour les troubles dépressifs à 1,95 EUR (1,30-2,60) et pour les troubles anxieux à 1,14 EUR (0,76-1,52).Financer les psychothérapies s’avère être un investissement rentable à court et long terme, d’autant plus que l’impact sur la rémission des troubles somatiques n’a pas été évalué. Le nombre de psychothérapeutes nécessaires s’avère suffisant pour cette prise en charge.Objectives Depressive or anxious disorders are a major source of social and economic burden. Many international good practice guidelines recommend structured psychotherapy for treating depressive or anxious disorders. The positive impact of psychotherapy on health, quality of life, productivity, and on the direct and indirect costs has been widely demonstrated. Nevertheless, the psychotherapies provided in private practice with a non-medical psychotherapist are not reimbursed to patients by French health cover systems.This article aims (1) to assess the cost and benefit of providing a funding program for psychotherapies for the community for French adults suffering from severe or recurrent depressive or anxious disorders, and (2) to estimate the number of psychotherapists that this program would be needed.Methods Data are based on the Enquête Indicateurs de santé mentale dans quatre régions françaises: a cross-sectional survey of a representative sample of 20,777 adults in the general population conducted in 2005. The questionnaires were administered by a telephone interview with the Composite International Diagnostic Interview – short form. A financial evaluation of covering the cost of psychotherapies was performed using the methodology of the British program Improving Access for Psychological Therapies adapted to the Fre...

show abstract

“…Some researchers found that different psychotherapies are effective in preventing relapse/recurrence Hollon & Ponniah, 2010;Steinert et al 2014;Biesheuvel-Leliefeld et al 2015) and that their enduring effects are as effective as a continuous use of medications (Cuijpers et al 2013b). In contrast, others have shown that the superiority of EBT for acute depression and anxiety disorders over TAU is minimal on 0-4-month follow-ups, and does not extend at 8-12-month follow-ups (Flückiger et al 2014).…”

Section: Enduring Effects Of Psychotherapymentioning

confidence: 99%

What we know, what we do not know, and where are we heading? Efficacy and acceptability of psychological interventions for depression

Solomonov

Barber

2015

Epidemiol Psychiatr Sci

View full text Add to dashboard Cite

In the past several decades, increasing evidence supports the efficacy of psychotherapies for depression. The vast majority of findings from meta-analyses, randomized clinical trials (RCTs) and naturalistic studies have demonstrated that well-established psychotherapies (behavioural activation, problem-solving therapy, psychodynamic therapy, cognitive-behavioural therapy, interpersonal therapy and emotion-focused therapy) are superior to no-treatment and control conditions, and are in most cases equally effective in treating depression. However, despite this abundant support for psychotherapies, studies have also consistently shown high drop-out rates, high percentages of non-respondent patients who experience treatment failures, and mixed findings regarding the enduring effects of psychotherapy. Thus, there is a need to develop more personalised treatment models tailored to patients' needs. A new integrative sequential stepwise approach to the treatment of depression is suggested. Key words: Behaviour therapy, cognitive therapy, depression, evidence-based psychiatry, psychoanalysis and psychodynamic therapies. What do we know about the efficacy of psychotherapies for depression?Depression is a pervasive mental condition which interferes with all domains of one's functioning and it is one of the most common problems leading people to seek treatment (e.g. Summers & Barber, 2010). Recent studies have shown that the approximated cumulative incidence of depression diagnosis from childhood to adulthood is between 32.54 and 51% (Rohde et al. 2012;Angst et al. 2015).In the past several decades, over 400 randomised clinical trials have investigated the efficacy of psychotherapy for depression (Cuijpers, 2015). Despite the heated debate regarding the superiority of one treatment over others, there is fairly wide acceptance of the 'Dodo Bird Verdict ' (Luborsky et al. 1975), at least in the case of depression, suggesting that all treatments are more or less equally effective (Cuijpers et al. 2008;Barth et al. 2013). Furthermore, research in the past two decades has taught us that psychotherapeutic treatments of depression are superior to waitlist and other control conditions (Barth et al. 2013;Lambert, 2013), and that psychotherapy combined with anti-depressant medication is more effective than medication alone (Barber et al. 2013;Köhler et al. 2013;Hollon et al. 2014;Fonagy, 2015;Leichsenring et al. 2015). There is also evidence suggesting that some types of psychotherapies are not only as effective as medication, but also have higher long-term enduring effects (Hollon & Ponniah, 2010;Cuijpers et al. 2013b). We begin by briefly reviewing some of the major findings that have arisen from the literature on treatments of depression, focusing only on the best-known and more widely researched. Behavioural activation (BA)BA is one of the most accepted and widely used behavioural treatments. Meta analyses found BA to be as effective as cognitive-behavioural therapy, and superior to control conditions (Cuijpers et al. 2007;Mazzuc...

show abstract

Effectiveness of psychological interventions in preventing recurrence of depressive disorder: Meta-analysis and meta-regression

Abstract: We conclude that there is supporting evidence that preventive psychological interventions reduce the risk of relapse or recurrence in major depression.

Cited by 143 publications

References 59 publications

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress

Coûts et bénéfices d’un programme de financement des psychothérapies auprès des Français souffrant de troubles dépressifs ou anxieux

What we know, what we do not know, and where are we heading? Efficacy and acceptability of psychological interventions for depression

Contact Info

Product

Resources

About